Andrea Necchi, Head of Genitourinary Medical Oncology at Ospedale San Raffaele, shared on X:
“Another option for 2L therapy of advanced clear cell RCC? Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011).”
Title: Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
Authors: Robert J Motzer, Ray McDermott, Se Hoon Park, Mauricio Burotto, Roberto Iacovelli, Elena Verzoni, Cristina Suárez, Masatoshi Eto, Hernan J Cutuli, Camillo Porta, Ray Manneh Kopp, Sylvie Rottey, Guillermo de Velasco, Begoña P Valderrama, Arun A Azad, Ugo De Giorgi, Michel Pavic, Piotr Tomczak, Robert Figlin, Hans M Westgeest, Annalisa Guida, Andrea Necchi, Fabio A Schutz, Britt B M Suelmann, John B A G Haanen, Sammy Shuai Yuan, Rodolfo F Perini, Ding Wang, Daniel Y C Heng, Manuela Schmidinger.
Read the full article.
This also can be interesting:
LITESPARK-011 Trial: Belzutifan Plus Lenvatinib vs Cabozantinib in Advanced RCC
